A thiazolinethione derivative or a salt thereof and its applications

Thiazolinthion derivatives, as peptide amidation reagents, achieve highly selective modification of side-chain amino groups through aqueous phase reaction, solving the problem of poor selectivity in existing technologies, improving product purity and production efficiency, and reducing costs.

CN123106573APending Publication Date: 2026-11-17ASYMCHEM LIFE SCI TIANJIN +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611630219.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-21
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The poor selectivity of side chain amino modifications in existing peptides or proteins leads to increased side reactions, low product purity, and high production efficiency and cost.

Method used

Thiazoline-2-thione derivatives or their salts are used as peptide amidation reagents. By performing an amidation reaction with peptides in an aqueous system, thiazoline-2-thione is used as a leaving group to achieve highly selective modification of side chain amino groups.

Benefits of technology

It improves the yield and purity of amidation products, reduces purification process costs, has wide applicability, reduces by-products, and is suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106573A_ABST
    Figure CN123106573A_ABST
Patent Text Reader

Abstract

This application provides a thiazolinethion derivative or a salt thereof, relating to the field of organic synthesis technology. The thiazolinethion derivative has the structure shown in Formula I: ; wherein, R1 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one substituent from C1-C8 alkyl, C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy; R2 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one substituent from C1-C8 alkyl, C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy; R1 and R2 may be the same or different; n is an integer from 1 to 50. Based on the thiazolinethion derivative of this application, the technical problem of poor selectivity of activated esters for side-chain amino groups in the prior art is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of organic synthesis technology, and more specifically, to a thiazolinethion derivative or a salt thereof and its applications. Background Technology

[0002] Peptides and proteins, as important biological macromolecules, have wide applications in drug development, basic biological research, and materials science. In the modification of peptides or proteins, amino groups are among the most common reaction sites, widely used for introducing fluorescent labels, linking PEG chains, immobilizing on carrier surfaces, or forming cyclic structures.

[0003] In natural amino acids, amino groups mainly exist in two positions: one is the α-amino group attached to the α-carbon atom, which is the basic group that constitutes the backbone of the polypeptide and participates in the formation of peptide bonds; the other is the side chain amino group located on the side chain of the amino acid, such as the ε-amino group at the end of the lysine side chain and the β-amino and γ-amino groups in non-natural amino acids.

[0004] Existing methods for modifying the side chain amino groups in peptides or proteins primarily rely on condensation reactions between the amino group and activated carboxylic acid derivatives, such as N-hydroxysuccinimide esters or 2,4-dichloro-6-sulfonic acid phenol esters, to form stable amide bonds. However, when reacting with peptides (such as smegglutinin precursors), the selectivity for the target side chain amino group is poor, and side reactions with other nucleophilic groups (such as the N-terminal α-amino group) are easily observed, leading to increased byproducts and low product purity. Subsequent purification typically relies on costly preparative high-performance liquid chromatography (prep-HPLC) with significant yield losses, resulting in low production efficiency and increased production costs.

[0005] Therefore, it is of great significance to develop highly selective amidation reagents for selective modification of side chain amino groups. Summary of the Invention

[0006] The main objective of this application is to provide a thiazoline thione derivative and its application, in order to solve the technical problem of poor selectivity of activated esters for side chain amino groups in the prior art.

[0007] To achieve the above objectives, this application provides a thiazolinethion derivative or a salt thereof, the thiazolinethion derivative having the structure shown in Formula I:

[0008] ;

[0009] Wherein, R1 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of the substituents of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy;

[0010] R2 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy.

[0011] R1 and R2 may be the same or different;

[0012] n is an integer from 1 to 50.

[0013] Furthermore, R1 is selected from C1-C8 alkyl or benzyl, and R2 is selected from hydrogen.

[0014] Furthermore, the thiazolinethione derivative is selected from at least one of the following compounds:

[0015] ,

[0016] .

[0017] In a second aspect, this application provides the use of the above-mentioned thiazolinethion derivatives or their salts in the aminoacylation of amino acids, polypeptides or proteins, wherein the amino acids, polypeptides and proteins respectively contain side chain amino groups.

[0018] In a third aspect, this application provides the use of the above-mentioned thiazoline thione derivative or its salt in the preparation of glucagon-like peptide-1 receptor agonist polypeptide drugs for the treatment of diabetes or obesity.

[0019] In a fourth aspect, this application provides a method for amidation of a polypeptide, comprising the following steps: the polypeptide and the above-mentioned thiazoline thione derivative or its salt are subjected to an amidation reaction in an aqueous system to obtain an amidated product; the pH value of the amidation reaction is 5 to 13.5, and the temperature is -15°C to 50°C; the polypeptide contains a side chain amino group.

[0020] Furthermore, the aqueous phase system includes a phosphate buffer solution and a first organic solvent; by volume percentage, the proportion of the phosphate buffer solution in the aqueous phase system is greater than or equal to 80% and less than 100%; the first organic solvent is selected from at least one of N,N-dimethylformamide, N-methylpyrrolidone, acetonitrile, and acetone.

[0021] Furthermore, the pH value of the amidation reaction is between 10 and 13.

[0022] Furthermore, the molar ratio of the thiazolinethion derivative or its salt to the polypeptide is 1:1 to 1:2.

[0023] Furthermore, the amidation reaction is carried out at temperatures ranging from -15°C to 25°C.

[0024] Furthermore, after the amidation reaction is completed, the leaving groups released from the thiazoline thione derivative or its salt in the aqueous phase system after the reaction are recovered by organic solvent extraction. The organic solvent extraction method uses a second organic solvent for extraction, which is selected from at least one of ethyl acetate, isopropyl acetate, methyl tert-butyl ether, and dichloromethane.

[0025] Furthermore, the thiazolinethione derivative has the structure shown in Formula I:

[0026] ;

[0027] Wherein, R1 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of the substituents of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy;

[0028] R2 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy.

[0029] R1 and R2 may be the same or different;

[0030] n is 16;

[0031] The structure of the polypeptide is shown in Formula II:

[0032] ;

[0033] II;

[0034] The structure of the amidation product is shown in Formula III:

[0035] ;

[0036] III.

[0037] By applying the technical solution of this application, a thiazoline-2-thione derivative having a specific structure of Formula I is used as a polypeptide amidation reagent to replace the activated ester in the prior art. In its molecular structure, thiazoline-2-thione is a leaving group, which has high selectivity for amidation of side chain amino groups, which is beneficial to obtaining amidation products with high yield and high purity.

[0038] Thiazolinthion derivatives, as novel peptide amidation reagents, can achieve highly selective amidation of side chain amino groups within a wide pH window and at low temperatures, thus having broader applicability.

[0039] The leaving group thiazoline-2-thione in thiazoline-thione derivatives can be efficiently recovered and recycled through organic solvent extraction and other methods. Meanwhile, thiazoline-thione derivatives exhibit good chemical stability during the reaction process, with low hydrolysis loss and reduced types and quantities of byproducts. This reduces reliance on complex and expensive purification processes, lowers purification and material costs, and is beneficial for large-scale production. Detailed Implementation

[0040] It should be noted that, unless otherwise specified, the embodiments and features described in this application can be combined with each other. The present application will now be described in detail with reference to the embodiments.

[0041] As described in the background section, the prior art suffers from poor selectivity of activated esters for side-chain amino groups. To address this problem, this application provides a thiazolinethion derivative or a salt thereof, the thiazolinethion derivative having the structure shown in Formula I:

[0042] ;

[0043] Wherein, R1 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of the substituents of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy;

[0044] R2 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy.

[0045] R1 and R2 may be the same or different;

[0046] n is an integer from 1 to 50.

[0047] In the prior art, activated esters refer to ester derivatives with higher reactivity formed by chemical modification of carboxylic acids (-COOH). The carbonyl carbon in the ester group is more susceptible to attack by nucleophiles (such as amino groups -NH2), thereby efficiently forming amide bonds (-CONH-) under mild conditions and releasing a leaving group.

[0048] N-hydroxysuccinimide esters exhibit poor chemical stability and are readily hydrolyzed in aqueous solutions, leading to feedstock waste and uncontrollable reactions. Compared to N-hydroxysuccinimide esters, 2,4-dichloro-6-sulfonic acid phenol esters show improved stability, but they require strongly alkaline conditions (e.g., pH 11 to 13) to achieve high selectivity. Furthermore, the leaving group of sulfonic acid phenol esters is a water-soluble sulfonic acid derivative, making extraction and recovery difficult and resulting in low feedstock utilization.

[0049] In this application, a thiazoline-2-thione derivative having a specific structure of Formula I is used as a polypeptide amidation reagent to replace the activated ester in the prior art. In its molecular structure, thiazoline-2-thione is a leaving group, which has high selectivity for amidation of the side chain amino group, which is beneficial to obtaining amidation products with high yield and high purity.

[0050] Thiazolinthion derivatives, as novel peptide amidation reagents, can achieve highly selective amidation of side chain amino groups within a wide pH window and at low temperatures, thus having broader applicability.

[0051] The leaving group thiazoline-2-thione in thiazoline-thione derivatives can be efficiently recovered and recycled through organic solvent extraction and other methods. Meanwhile, thiazoline-thione derivatives exhibit good chemical stability during the reaction process, with low hydrolysis loss and reduced types and quantities of byproducts. This reduces reliance on complex and expensive purification processes, lowers purification and material costs, and is beneficial for large-scale production.

[0052] It should be noted that, in this application, the thiazolinethion derivative having a specific structure of Formula I may include, but is not limited to, sodium salts, potassium salts, calcium salts, magnesium salts, aluminum salts, zinc salts, lithium salts, ammonium salts, trimethylamine salts, pyridine salts, etc.

[0053] In some embodiments, R1 is selected from C1-C8 alkyl or benzyl, and R2 is selected from hydrogen.

[0054] In the technical solution of this application embodiment, when R1 is selected from the above-mentioned specific substituents and R2 is hydrogen, high selectivity and high activity of amidation of the side chain amino group can be achieved, which is beneficial to obtaining amidation products with high yield and high purity.

[0055] In some embodiments, the thiazolinethion derivative is selected from at least one of the following compounds:

[0056] ,

[0057] .

[0058] In a second aspect, this application provides the use of the above-mentioned thiazolinethion derivatives or their salts in the aminoacylation of amino acids, polypeptides or proteins, wherein the amino acids, polypeptides and proteins respectively contain side chain amino groups.

[0059] In this application, the side-chain amino group refers to the amino group (-NH2) located on the side chain (R group) of an amino acid residue, and its side chain structure is -(CH2). n-NH2 (n≥1), specifically, the side chain amino group has the following characteristics: the amino group is not directly attached to the α-carbon atom of the amino acid backbone, but is attached to a specific position of the side chain carbon chain (such as β, γ, δ, ε sites).

[0060] As an example, side-chain amino groups include, but are not limited to, the following types: β-amino: an amino group attached to the second carbon atom (β-carbon) of the side chain; γ-amino: an amino group attached to the third carbon atom (γ-carbon) of the side chain; δ-amino: an amino group attached to the fourth carbon atom (δ-carbon) of the side chain; ε-amino: an amino group attached to the fifth carbon atom (ε-carbon) of the side chain. In lysine residues, the side chain structure is -(CH2)4-NH2.

[0061] In the technical solution of this application, the thiazolinethion derivative has a high specific recognition and reaction ability for side chain amino groups (such as the ε-amino group in lysine). The selectivity for side chain amino groups is higher than that for nucleophilic sites of other amino acids, such as the N-terminal α-amino group. It can achieve site-specific modification in complex peptide and protein systems, and solves the problem of multi-site acylation that is easy to occur in traditional activated esters.

[0062] In a third aspect, this application provides the use of the above-mentioned thiazoline thione derivative or its salt in the preparation of glucagon-like peptide-1 receptor (GLP-1) agonist polypeptide drugs for the treatment of diabetes or obesity.

[0063] The widespread use of glucagon-like peptide-1 receptor agonist peptide drugs (such as semaglutide) in the treatment of type 2 diabetes and obesity hinges on their industrial production. The key to this lies in the highly selective amidation of the side chain amino groups at specific sites on the peptide, such as the lysine residue (Lys26) at position 26 in semaglutide. Developing highly selective amidation reagents is of great significance for the preparation of GLP-1 receptor agonist peptide drugs such as semaglutide.

[0064] In the technical solution of this application, the thiazoline thione derivative can be used for the amidation synthesis of the side chain amino groups of glucagon-like peptide-1 receptor agonist polypeptide drugs such as smegglutide and liraglutide. The prepared product has high purity and simple impurity spectrum, which can significantly reduce the subsequent purification cost and improve batch consistency, providing technical support for the low-cost production of such diabetes and obesity treatment drugs.

[0065] In a fourth aspect, this application provides a method for amidation of a polypeptide, comprising the following steps: the polypeptide and the above-mentioned thiazoline thione derivative or its salt are subjected to an amidation reaction in an aqueous system to obtain an amidated product; the pH value of the amidation reaction is 5 to 13.5, and the temperature is -15°C to 50°C; the polypeptide contains a side chain amino group.

[0066] In the technical solution of this application embodiment, the amidation method of peptides uses thiazoline thione derivatives as amidation reagents, which can achieve high selectivity and high yield amidation of side chain amino groups under a wide process window such as pH value window and mild temperature window, and has both high reaction efficiency and high purity.

[0067] In this application, the pH value of the amidation reaction can be a value within the range of 5, 6, 7, 8, 9, 10, 11, 12, 13, 13.5 or any combination thereof, without further limitation herein.

[0068] In this application, the temperature of the amidation reaction can be a value within the range of -15℃, -10℃, -5℃, 5℃, 10℃, 15℃, 20℃, 25℃, 30℃, 35℃, 40℃, 45℃, 50℃, or any combination thereof.

[0069] In this application, the aqueous phase system refers to a reaction medium system in which water is the only solvent or water is the main solvent and organic solvents are auxiliary components, wherein the volume ratio of water is not less than 50% of the total solvent volume, preferably 70% to 100%.

[0070] In some embodiments, the aqueous phase system includes a phosphate buffer solution and a first organic solvent; the phosphate buffer solution accounts for more than or equal to 80% and less than 100% of the aqueous phase system by volume percentage; the first organic solvent is selected from at least one of N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), acetonitrile, and acetone.

[0071] In the technical solution of this application embodiment, the aqueous phase system includes a phosphate buffer solution and a first organic solvent. The buffer solution accounts for ≥80% of the aqueous phase system. The phosphate buffer solution has good pH buffering capacity, avoiding side reactions caused by local pH fluctuations. At the same time, the introduction of low polarity solvents such as DMF and NMP into the aqueous phase system can improve the solubility of the reaction raw material thiazoline thione derivative, thereby increasing the reaction rate and reducing side reactions caused by local concentration fluctuations.

[0072] In some embodiments, the concentration of phosphate in the phosphate buffer solution is 0.05 mol / L to 0.5 mol / L, based on phosphate ions. The aqueous system has good pH buffering capacity, which is beneficial for obtaining high-purity target products.

[0073] In some embodiments, the step of performing an amidation reaction between the polypeptide and a thiazoline thione derivative or its salt in an aqueous system includes: dissolving the polypeptide in a phosphate buffer solution to obtain an aqueous polypeptide solution; dissolving the thiazoline thione derivative or its salt in a first organic solvent to obtain a thiazoline thione derivative solution; and adding the thiazoline thione derivative solution to the aqueous polypeptide solution to carry out the amidation reaction. By dissolving the two separately to prepare solutions and then mixing them, the solubility of the reactant thiazoline thione derivative can be improved, the reaction rate can be increased, and side reactions caused by local concentration fluctuations can be reduced.

[0074] In some preferred embodiments, the phosphate buffer solution is obtained by mixing an aqueous solution of disodium hydrogen phosphate and an aqueous solution of sodium hydroxide; the step of dissolving the polypeptide in the phosphate buffer solution to obtain an aqueous polypeptide solution includes preparing an aqueous solution of disodium hydrogen phosphate, adding the polypeptide to the aqueous solution of disodium hydrogen phosphate to obtain a first mixed system, and adding an aqueous solution of sodium hydroxide dropwise to the first mixed system to adjust the pH of the first mixed system to 10 to 13 to obtain an aqueous polypeptide solution.

[0075] In some embodiments, the pH of the amidation reaction is 10 to 13, which is beneficial for obtaining the target product with high purity and high yield.

[0076] In some embodiments, the molar ratio of the thiazoline thione derivative or its salt to the polypeptide is 1:1 to 1:2. Under the above-mentioned raw material ratio, the raw material conversion rate is high, the by-product content is low, the material cost is reduced, and it is beneficial to obtain the target product with high purity and high yield.

[0077] In some embodiments, the amidation reaction is carried out at a temperature of -15°C to 25°C, which is beneficial for obtaining the target product with high purity and high yield.

[0078] In some embodiments, after the amidation reaction is completed, the leaving groups released from the thiazoline thione derivative or its salt in the aqueous phase system after the reaction are recovered by organic solvent extraction; the organic solvent extraction method uses a second organic solvent for extraction, the second organic solvent being selected from at least one of ethyl acetate, isopropyl acetate, methyl tert-butyl ether, and dichloromethane.

[0079] In the technical solution of this application embodiment, in the polypeptide amidation process, organic solvents such as ethyl acetate and isopropyl acetate are used as extractants to recover the leaving group thiazoline-2-thione released after the reaction. The recovered leaving group can be recycled for the synthesis of thiazoline-2-thione derivatives.

[0080] In some embodiments, the thiazolinethione derivative has the structure shown in Formula I:

[0081] ;

[0082] Wherein, R1 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of the substituents of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy;

[0083] R2 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy.

[0084] R1 and R2 may be the same or different;

[0085] n is 16;

[0086] The structure of the polypeptide is shown in Formula II:

[0087] ;

[0088] II;

[0089] The structure of the amidation product is shown in Formula III:

[0090] ;

[0091] III.

[0092] The complete amino acid sequence of smegglutinin (from N-terminus to C-terminus) is as follows: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(side-chain)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH, as shown in Formula A. This sequence contains 31 standard amino acid residues, of which the first position is a histidine derivative (His), which is an N-terminal modification to enhance stability. The side chain structure of the lysine residue at position 26 in the peptide backbone is: -CH2-CH2-CH2-CH2-NH2, and its ε-amino group is the selective amidation site of the thiazolinethion derivative of this application. This ε-amino group is linked to the fatty acid chain through an amide bond to form a stable covalent structure.

[0093] ;

[0094] A.

[0095] In the technical solution of this application embodiment, the ε-amino group of the lysine residue in the polypeptide represented by Formula II can undergo selective amidation reaction with the above-mentioned thiazoline thione derivative to reduce the content of stereoisomer impurities and double coupling impurities (amidation products in which both the α-amino group in the N-terminal glutamic acid and the ε-amino group of the lysine residue are amidated), thereby obtaining a high-purity amidation product represented by Formula III. As a precursor of smegglutinin, smegglutinin can be obtained by further coupling the amidation product represented by Formula III with His-Aib dipeptide.

[0096] In some preferred embodiments, after the amidation reaction is completed, the aqueous phase system after the reaction is completed is separated and purified to obtain the amidation product; the separation and purification includes adjusting the pH of the aqueous phase system after the reaction to 4 to 5 and then performing solid-liquid separation.

[0097] In the technical solution of this application embodiment, by adjusting the pH value of the aqueous phase system after the reaction to 4 to 5, the product can be acidified and precipitated without relying on complex separation and purification methods such as Prep-HPLC. Furthermore, the product has high purity and high yield, the steps are simple, the production cycle is significantly shortened, and equipment and energy costs are reduced. Specifically, the pH value of the aqueous phase system after the reaction can be adjusted using acids such as trifluoroacetic acid, hydrochloric acid, phosphoric acid, sulfuric acid, hydrobromic acid, methanesulfonic acid, and p-toluenesulfonic acid.

[0098] This application also provides a method for preparing a thiazolinethion derivative, comprising the following steps:

[0099] The side-chain carboxylic acid precursor shown in Formula a is dissolved in dichloromethane (DCM) to obtain a side-chain carboxylic acid precursor solution; thiazoline-2-thione, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), and 4-dimethylaminopyridine (DMAP) shown in Formula b are mixed with the side-chain carboxylic acid precursor solution to obtain a first mixed system; the first mixed system is stirred and reacted at 15°C to 25°C for 0.5 to 5 h to obtain a second mixed system;

[0100] Add a mixed solvent of water and acetic acid to the second mixed reaction system, then add acetonitrile to promote the separation of the two phases. After mixing, let the mixture stand to separate the phases, and retain the organic phase. Wash the organic phase sequentially with a mixed solvent of acetic acid and water and a saturated sodium chloride aqueous solution, and then concentrate it under reduced pressure at below 35°C until no distillation occurs, to obtain the oily crude product of the intermediate product shown in formula e.

[0101] The oily crude product of the intermediate product shown in Formula e is cooled to 0°C to 5°C, and then trifluoroacetic acid is added for acid hydrolysis. After acid hydrolysis, the product is concentrated under reduced pressure below 35°C until no distillation occurs, to obtain the crude product of the target product. The crude product of the target product is added to methyl tert-butyl ether (MTBE) pre-cooled to -40°C to -25°C, and the product precipitates. Solid-liquid separation is performed to obtain the thiazolinthion derivative shown in Formula I.

[0102] .

[0103] The present application will be further described in detail below with reference to specific embodiments, which should not be construed as limiting the scope of protection claimed in the present application.

[0104] Example 1

[0105] An amidation method for a polypeptide includes the following steps:

[0106] Step 1: Prepare the thiazolinethion derivative shown in Formula I-1:

[0107] At 20°C, 100 mL of dichloromethane was added to a 500 mL reaction flask, and magnetic stirring was started. 20.0 g (1.0 equivalent) of the side-chain carboxylic acid precursor shown in formula a was added to the dichloromethane, and the mixture was stirred to dissolve, yielding a side-chain carboxylic acid precursor solution. 4-Benzylthiazoline-2-thione was then added sequentially to the side-chain carboxylic acid precursor solution. ) (1.03 equivalent), EDCI (2.0 equivalent) and DMAP (0.2 equivalent) were stirred and mixed to obtain a first mixture system. The first mixture system was stirred and reacted at 20°C for 1 hour to obtain a second mixture system;

[0108] Add 200 mL of a mixed solvent of water and acetic acid (volume ratio of water to acetic acid is 1:1) to the second mixture, add a small amount of 10 mL of acetonitrile to promote the separation of the two phases, let stand and separate the liquids, retaining the organic phase; wash the organic phase once with a mixed solvent of acetic acid and water (volume ratio of acetic acid and water is 1:1), and then wash it four times with a saturated sodium chloride aqueous solution. After washing, concentrate the organic phase by vacuum distillation at 35 °C until no distillate is produced, to obtain the oily crude product of the intermediate product shown in formula c-1;

[0109] The oily crude product of the intermediate shown in formula c-1 was cooled to 0°C, and 160 mL of trifluoroacetic acid was added. The mixture was stirred and acidified at 0°C for 1 hour. After acidification, it was distilled under reduced pressure at 35°C until no distillate was observed, yielding the crude product. 150 mL of MTBE was pre-cooled to -30°C in a mixed bath of dry ice and ethanol. The concentrated crude product was added dropwise to the pre-cooled MTBE, causing a precipitate to form. The precipitate was collected by suction filtration, and the filter cake was washed with 50 mL of pre-cooled MTBE to obtain the solid product of the thiazolinthion derivative shown in formula I-1, with a purity of 90%. Analysis by liquid chromatography-mass spectrometry (LC-MS) showed a retention time RT of 30.28 min and a molecular ion peak [M+H]. + Its mass-to-charge ratio (m / z) is 925.5;

[0110] .

[0111] Step 2: At 20℃, add 20 mL of 0.2 mol / L disodium hydrogen phosphate aqueous solution to a 250 mL reaction flask. While stirring, add 0.5 g (1.0 equivalent) of the polypeptide shown in Formula II to the disodium hydrogen phosphate aqueous solution to obtain a polypeptide dispersion, which is turbid. Add 0.5 mol / L sodium hydroxide aqueous solution dropwise to the polypeptide dispersion to adjust the pH of the system to 11.3. The system becomes clear, and then add pure water to bring the total volume of the system to 25 mL to obtain an aqueous polypeptide solution.

[0112] ;

[0113] II.

[0114] Step 3: Dissolve the thiazolinethion derivative (1.25 equivalents) shown in Formula I-1 in 1 mL of N-methylpyrrolidone to obtain a thiazolinethion derivative solution.

[0115] Step 4: Under stirring conditions at 20℃, the thiazoline thione derivative solution is added dropwise to the polypeptide aqueous solution. During the dropwise addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 11.3. The dropwise addition of the thiazoline thione derivative solution takes 5 min. After the dropwise addition of the thiazoline thione derivative solution is completed, the reaction is stirred at 20℃ for another 5 min to obtain a mixed reaction solution.

[0116] Step 5: Isopropyl acetate was added to the mixed reaction solution for extraction, and the extraction was performed three times, 5 ml each time. The organic phases were combined, and the aqueous phase was retained. Trifluoroacetic acid was added to the aqueous phase to adjust the pH to 4, causing the product to precipitate. The aqueous phase was filtered to obtain a solid, which was dried at 35°C for 24 h to obtain the amidated product shown in Formula III. LC-MS analysis showed an RT of 21.96 min and a molecular ion peak of [M+H].+ The m / z value is 1297.3350;

[0117] ;

[0118] III.

[0119] Example 2

[0120] The only difference between it and Example 1 is that:

[0121] Step 1: Prepare the thiazolinethion derivative shown in Formula I-2:

[0122] At 20°C, 100 mL of dichloromethane was added to a 500 mL reaction flask, and magnetic stirring was started. 8.0 g (1.0 equivalent) of the side-chain carboxylic acid precursor shown in formula a was added to the dichloromethane, and the mixture was stirred to dissolve, yielding a side-chain carboxylic acid precursor solution. 4-Isopropylthiazoline-2-thione was then added sequentially to the side-chain carboxylic acid precursor solution. ) (1 equivalent), EDCI (2.0 equivalent) and DMAP (0.5 equivalent) were stirred and mixed to obtain a first mixed system. The first mixed system was stirred and reacted at 20°C for 1 hour to obtain a second mixed system;

[0123] Add 200 mL of a mixed solvent of water and acetic acid (volume ratio of water to acetic acid is 1:1) to the second mixture, add 10 mL of acetonitrile to promote the separation of the two phases, let stand and separate the liquids, retaining the organic phase; wash the organic phase once with a mixed solvent of acetic acid and water (volume ratio of acetic acid and water is 1:1), and then wash it four times with a saturated sodium chloride aqueous solution. After washing, concentrate the organic phase by vacuum distillation at 35 °C until no distillate is produced, to obtain the oily crude product of the intermediate product shown in formula c-2.

[0124] The oily crude product of the intermediate shown in formula c-2 was cooled to 0°C, and 160 mL of trifluoroacetic acid was added. The mixture was stirred and acidified at 0°C for 1 hour. After acidification, the product was concentrated by vacuum distillation at 35°C until no more distillate was observed, yielding the crude product. 150 mL of MTBE was pre-cooled to -30°C in a mixed bath of dry ice and ethanol. The concentrated crude product was added dropwise to the pre-cooled MTBE, resulting in a solid precipitate. The precipitate was collected by suction filtration, and the filter cake was washed with 50 mL of pre-cooled MTBE to obtain the solid product of the thiazolinethion derivative shown in formula I-2. The product purity was 91%. LC-MS analysis showed an RT of 24.19 min and a molecular ion peak of [M+H]. + Its m / z is 877.6;

[0125] .

[0126] Step 2: At 20°C, add 20 mL of 0.2 mol / L disodium hydrogen phosphate aqueous solution to a 250 mL reaction flask. While stirring, add 0.5 g (1.0 equivalent) of the polypeptide represented by Formula II to the disodium hydrogen phosphate aqueous solution to obtain a polypeptide dispersion, which is turbid. Adjust the pH of the system to 11.3 by adding 0.5 mol / L sodium hydroxide aqueous solution dropwise to the polypeptide dispersion. The system becomes clear, and then pure water is added to bring the total volume of the system to 25 mL to obtain an aqueous polypeptide solution.

[0127] Step 3: Dissolve the thiazolinethion derivative (1.25 equivalents) shown in Formula I-2 in 1 mL of N-methylpyrrolidone to obtain a thiazolinethion derivative solution.

[0128] Step 4: Under stirring conditions at 20℃, the thiazoline thione derivative solution is added dropwise to the polypeptide aqueous solution. During the dropwise addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 11.3. The dropwise addition of the thiazoline thione derivative solution takes 5 min. After the dropwise addition of the thiazoline thione derivative solution is completed, the reaction is stirred at 20℃ for another 5 min to obtain a mixed reaction solution.

[0129] Step 5: Isopropyl acetate was added to the mixed reaction solution for extraction. The extraction was repeated 3 times, 5 ml each time. The organic phases were combined, and the aqueous phase was retained. Trifluoroacetic acid was added to the aqueous phase to adjust the pH to 4. The product precipitated out. The aqueous phase was filtered to obtain a solid. The solid was dried at 35°C for 24 h to obtain the amidated product shown in Formula III.

[0130] Example 3

[0131] The only difference between it and Example 1 is that:

[0132] In step two, 0.5 mol / L HCl aqueous solution is added dropwise to the peptide dispersion to adjust the pH of the system to 7.

[0133] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L HCl aqueous solution is added dropwise to maintain the pH of the system at 7.

[0134] Example 4

[0135] The only difference between it and Example 1 is that:

[0136] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 10.2.

[0137] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 10.2.

[0138] Example 5

[0139] The only difference between it and Example 1 is that:

[0140] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 12.2.

[0141] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 12.2.

[0142] Example 6

[0143] The only difference between it and Example 2 is that:

[0144] In step two, 0.5 mol / L HCl aqueous solution is added dropwise to the peptide dispersion to adjust the pH of the system to 7.

[0145] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L HCl aqueous solution is added dropwise to maintain the pH of the system at 7.

[0146] Example 7

[0147] The only difference between it and Example 2 is that:

[0148] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 10.2.

[0149] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 10.2.

[0150] Example 8

[0151] The only difference between it and Example 2 is that:

[0152] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 12.2.

[0153] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 12.2.

[0154] Example 9

[0155] The only difference between this example and Example 1 is that the reaction temperature in step four is 0°C. Step four is as follows:

[0156] Under stirring conditions at 0℃, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the dropwise addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The dropwise addition of the thiazoline thione derivative solution took 5 min. After the dropwise addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 0℃ for another 5 min to obtain a mixed reaction solution.

[0157] Example 10

[0158] The only difference between this example and Example 1 is that the reaction temperature in step four is 10°C. Step four is as follows:

[0159] At 10°C and under stirring conditions, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The addition of the thiazoline thione derivative solution took 5 min. After the addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 10°C for another 5 min to obtain a mixed reaction solution.

[0160] Example 11

[0161] The only difference between this example and Example 2 is that the reaction temperature in step four is 0°C. Step four is as follows:

[0162] Under stirring conditions at 0℃, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the dropwise addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The dropwise addition of the thiazoline thione derivative solution took 5 min. After the dropwise addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 0℃ for another 5 min to obtain a mixed reaction solution.

[0163] Example 12

[0164] The only difference between this example and Example 2 is that the reaction temperature in step four is 10°C. Step four is as follows:

[0165] At 10°C and under stirring conditions, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The addition of the thiazoline thione derivative solution took 5 min. After the addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 10°C for another 5 min to obtain a mixed reaction solution.

[0166] Example 13

[0167] The only difference between this and Example 1 is that in step two, pure water is added until the total volume of the system is 40 mL.

[0168] Comparative Example 1

[0169] An amidation method for a polypeptide includes the following steps:

[0170] Step 1: Prepare the N-hydroxysuccinimide ester shown in Ia:

[0171] At 20°C, 100 mL of tetrahydrofuran (THF) was added to a 500 mL reaction flask, and magnetic stirring was started. 10.0 g (1.0 equivalent) of the side-chain carboxylic acid precursor shown in formula a was added to the THF, and the mixture was stirred to dissolve, yielding a side-chain carboxylic acid precursor solution. 2-Succinimidyl-1,1,3,3-tetramethylurea tetrafluoroborate was added sequentially to the side-chain carboxylic acid precursor solution. (1.6 equivalents) and N,N-diisopropylethylamine (DIPEA) (1.6 equivalents) were stirred and mixed to obtain the first mixed system. The first mixed system was stirred and reacted at 20°C for 1 hour to obtain the second mixed system.

[0172] The second mixture was filtered, and the filter cake was washed with 20 ml of THF. The filtrates were combined and collected. The filtrate was concentrated by vacuum distillation at 35°C until no more distillate was produced, yielding the crude product of the intermediate shown in formula d.

[0173] The crude product obtained from the intermediate shown in formula d was cooled to 0°C, and 50 mL of trifluoroacetic acid was added. The mixture was stirred and acidified at 0°C for 1 hour. After acidification, it was distilled under reduced pressure at 35°C until no distillate was observed, yielding the crude product. 150 mL of MTBE was pre-cooled to -30°C in a mixed bath of dry ice and ethanol. The concentrated crude product was added dropwise to the pre-cooled MTBE, resulting in a solid precipitate. The precipitate was collected by suction filtration, and the filter cake was washed with 50 mL of pre-cooled MTBE to obtain the solid product of N-hydroxysuccinimide ester shown in formula Ia, with a purity of 62%. LC-MS analysis showed an RT of 13.15 min and a molecular ion peak of [M+H]. + The m / z value is 831.6;

[0174] .

[0175] Step 2: At 20°C, add 20 mL of 0.2 mol / L disodium hydrogen phosphate aqueous solution to a 250 mL reaction flask. While stirring, add 0.5 g (1.0 equivalent) of the polypeptide represented by Formula II to the disodium hydrogen phosphate aqueous solution to obtain a polypeptide dispersion, which is turbid. Adjust the pH of the system to 11.3 by adding 0.5 mol / L sodium hydroxide aqueous solution dropwise to the polypeptide dispersion. The system becomes clear, and then pure water is added to bring the total volume of the system to 25 mL to obtain an aqueous polypeptide solution.

[0176] Step 3: Dissolve the N-hydroxysuccinimide ester (1.8 equivalents) shown in Ia in 1 mL of N-methylpyrrolidone to obtain an N-hydroxysuccinimide ester solution.

[0177] Step 4: Under stirring conditions at 20℃, N-hydroxysuccinimide ester solution is added dropwise to the polypeptide aqueous solution. During the addition of N-hydroxysuccinimide ester solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 11.3. The addition of N-hydroxysuccinimide ester solution takes 5 min. After the addition of N-hydroxysuccinimide ester solution is completed, the reaction is stirred at 20℃ for another 5 min to obtain a mixed reaction solution.

[0178] Step 5: Isopropyl acetate was added to the mixed reaction solution for extraction. The extraction was repeated 3 times, 5 ml each time. The organic phases were combined, and the aqueous phase was retained. Trifluoroacetic acid was added to the aqueous phase to adjust the pH to 4. The product precipitated out. The aqueous phase was filtered to obtain a solid. The solid was dried at 35°C for 24 h to obtain the amidated product shown in Formula III.

[0179] Comparative Example 2

[0180] An amidation method for a polypeptide includes the following steps:

[0181] Step 1: Preparation of phenolic 2,4-dichloro-6-sulfonic acid ester as shown in formula Ib:

[0182] At 20°C, 100 mL of THF was added to a 500 mL reaction flask, and magnetic stirring was started. 10.0 g (1.0 equivalent) of the side-chain carboxylic acid precursor shown in formula a was added to the THF, and the mixture was stirred to dissolve, yielding a side-chain carboxylic acid precursor solution. 2,4-Dichloro-6-sulfonic acid phenol ester (…) was then added sequentially to the side-chain carboxylic acid precursor solution. (1.12 equivalents) and triethylamine (TEA) (3.0 equivalents) were stirred and mixed to obtain the first mixture system. The first mixture system was stirred and reacted at 20°C for 1 hour to obtain the second mixture system.

[0183] The second mixture was filtered, and the filter cake was washed with 20 ml of THF. The filtrates were combined and collected. The filtrate was concentrated by vacuum distillation at 35 °C until no more distillate was produced, yielding the crude product of the intermediate shown in formula e.

[0184] The crude product obtained from the intermediate shown in formula e was cooled to 0°C, and 50 mL of trifluoroacetic acid was added. The mixture was stirred and acidified at 0°C for 1 hour. After acidification, the product was concentrated by vacuum distillation at 35°C until no more distillate was observed, yielding the crude product. 150 mL of MTBE was pre-cooled to -30°C in a mixed bath of dry ice and ethanol. The concentrated crude product was added dropwise to the pre-cooled MTBE, resulting in a solid precipitate. The precipitate was collected by suction filtration, and the filter cake was washed with 50 mL of pre-cooled MTBE to obtain the solid product of 2,4-dichloro-6-sulfonic acid phenol ester shown in formula Ib, with a purity of 90%. LC-MS analysis showed an RT of 12.63 min and a molecular ion peak [M+H]. + The m / z value is 958;

[0185] .

[0186] Step 2: At 20°C, add 20 mL of 0.2 mol / L disodium hydrogen phosphate aqueous solution to a 250 mL reaction flask. While stirring, add 0.5 g (1.0 equivalent) of the polypeptide represented by Formula II to the disodium hydrogen phosphate aqueous solution to obtain a polypeptide dispersion, which is turbid. Adjust the pH of the system to 11.3 by adding 0.5 mol / L sodium hydroxide aqueous solution dropwise to the polypeptide dispersion. The system becomes clear, and then pure water is added to bring the total volume of the system to 25 mL to obtain an aqueous polypeptide solution.

[0187] Step 3: Dissolve 2,4-dichloro-6-sulfonic acid phenol ester (1.3 equivalents) as shown in Formula Ib in 1 mL of N-methylpyrrolidone to obtain 2,4-dichloro-6-sulfonic acid phenol ester.

[0188] Step 4: Under stirring conditions at 20°C, 2,4-dichloro-6-sulfonic acid phenol ester was added dropwise to the polypeptide aqueous solution. During the dropwise addition of 2,4-dichloro-6-sulfonic acid phenol ester, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The dropwise addition of 2,4-dichloro-6-sulfonic acid phenol ester took 5 min. After the dropwise addition of 2,4-dichloro-6-sulfonic acid phenol ester was completed, the reaction was stirred at 20°C for another 5 min to obtain a mixed reaction solution.

[0189] Step 5: Isopropyl acetate was added to the mixed reaction solution for extraction. The extraction was repeated 3 times, 5 ml each time. The organic phases were combined, and the aqueous phase was retained. Trifluoroacetic acid was added to the aqueous phase to adjust the pH to 4. The product precipitated out. The aqueous phase was filtered to obtain a solid. The solid was dried at 35°C for 24 h to obtain the amidated product shown in Formula III.

[0190] Comparative Example 3

[0191] The only difference between it and Comparative Example 1 is that:

[0192] In step two, 0.5 mol / L HCl aqueous solution is added dropwise to the peptide dispersion to adjust the pH of the system to 7.

[0193] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L HCl aqueous solution is added dropwise to maintain the pH of the system at 7.

[0194] Comparative Example 4

[0195] The only difference between it and Comparative Example 1 is that:

[0196] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 10.2.

[0197] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 10.2.

[0198] Comparative Example 5

[0199] The only difference between it and Comparative Example 1 is that:

[0200] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 12.2.

[0201] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 12.2.

[0202] Comparative Example 6

[0203] The only difference between it and Comparative Example 2 is that:

[0204] In step two, 0.5 mol / L HCl aqueous solution is added dropwise to the peptide dispersion to adjust the pH of the system to 7.

[0205] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L HCl aqueous solution is added dropwise to maintain the pH of the system at 7.

[0206] Comparative Example 7

[0207] The only difference between it and Comparative Example 2 is that:

[0208] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 10.2.

[0209] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 10.2.

[0210] Comparative Example 8

[0211] The only difference between it and Comparative Example 2 is that:

[0212] In step two, 0.5 mol / L NaOH aqueous solution is added dropwise to the polypeptide dispersion to adjust the pH of the system to 12.2.

[0213] In step four, during the addition of the thiazolinethion derivative solution, 0.5 mol / L NaOH aqueous solution is added dropwise to maintain the pH of the system at 12.2.

[0214] Comparative Example 9

[0215] The only difference between this and Comparative Example 1 is that the reaction temperature in step four is 0°C. Step four is as follows:

[0216] Under stirring conditions at 0℃, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the dropwise addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The dropwise addition of the thiazoline thione derivative solution took 5 min. After the dropwise addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 0℃ for another 5 min to obtain a mixed reaction solution.

[0217] Comparative Example 10

[0218] The only difference between this and Comparative Example 1 is that the reaction temperature in step four is 10°C. Step four is as follows:

[0219] At 10°C and under stirring conditions, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The addition of the thiazoline thione derivative solution took 5 min. After the addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 10°C for another 5 min to obtain a mixed reaction solution.

[0220] Comparative Example 11

[0221] The only difference between this and Comparative Example 2 is that the reaction temperature in step four is 0°C. Step four is as follows:

[0222] Under stirring conditions at 0℃, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the dropwise addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The dropwise addition of the thiazoline thione derivative solution took 5 min. After the dropwise addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 0℃ for another 5 min to obtain a mixed reaction solution.

[0223] Comparative Example 12

[0224] The only difference between this and Comparative Example 2 is that the reaction temperature in step four is 10°C. Step four is as follows:

[0225] At 10°C and under stirring conditions, a thiazoline thione derivative solution was added dropwise to an aqueous peptide solution. During the addition of the thiazoline thione derivative solution, 0.5 mol / L NaOH aqueous solution was added dropwise to maintain the pH of the system at 11.3. The addition of the thiazoline thione derivative solution took 5 min. After the addition of the thiazoline thione derivative solution was completed, the reaction was stirred at 10°C for another 5 min to obtain a mixed reaction solution.

[0226] Performance testing

[0227] I. Product Purity Test: The mixed reaction solution in step four was analyzed using high performance liquid chromatography (HPLC). The purity of the target product (i.e., the amidated product shown in Formula III) and the content of impurities (such as residual raw peptide, stereoisomer impurities, and double-coupling impurities) are shown in Table 1, expressed as a percentage of peak area. Purity of the target product (%) = (peak area of ​​the target product) / (peak area of ​​the target product + sum of peak areas of all impurities), residual peptide (%) = (peak area of ​​the peptide) / (peak area of ​​the target product + sum of peak areas of all impurities), stereoisomer impurity content = (peak area of ​​stereoisomer impurity) / (peak area of ​​the target product + sum of peak areas of all impurities), double-coupling impurity content = (peak area of ​​double-coupling impurity).

[0228] II. Test of Leaving Group Recovery Effect

[0229] HPLC analysis was performed on the aqueous and organic phases after extraction in Example 1. The leaving group was mainly benzylthiazoline-2-thione ( It exists in the organic phase in the form of ) and can be effectively extracted and recovered by isopropyl acetate in the organic phase, with a recovery rate of 91%.

[0230] HPLC analysis was performed on the aqueous and organic phases after extraction in Example 2. The leaving group was mainly isopropylthiazoline-2-thione. It exists in the organic phase and can be effectively extracted and recovered by isopropyl acetate in the organic phase, with a recovery rate of 90%.

[0231] HPLC analysis was performed on the aqueous and organic phases after extraction in Comparative Example 2, and the leaving groups were analyzed. As a water-soluble sulfonic acid derivative, it is difficult to directly recover it in an aqueous system by extraction with isopropyl acetate in the organic phase, resulting in low raw material utilization.

[0232] Table 1

[0233]

[0234] Note: "-" in the table indicates that the corresponding substance was not detected.

[0235] As shown in Table 1, the amidation reagents used in Examples 1 to 14 as precursors of smegglutinin have a significantly high selectivity for the ε-amino group of the Lys side chain. After the reaction, the mixed reaction solution has low peptide residue, low content of stereoisomer impurities, low content of double coupling impurities, and high purity of the target product.

[0236] Comparisons of Examples 1, 9, 10, 2, 11, 12, Comparative Examples 1, 9, 10, 2, 11, and 12 show that when using thiazolinethion derivatives as amidating agents for the Lys side chain, the purity of the products in the mixed reactions at reaction temperatures of 0°C, 10°C, and 20°C is consistently higher than that of the systems using N-hydroxysuccinimide ester and 2,4-dichloro-6-sulfonic acid phenol ester as amidating agents at the corresponding temperatures. Under low-temperature conditions, thiazolinethion derivatives exhibit high selectivity for the ε-amino group of the Lys side chain.

[0237] As shown in Examples 1 and 3 to 5, using the thiazolinethion derivative of Formula I-1 as the amidation reagent for the Lys side chain, the product purity was lowest at pH 7 (72.96%), and the product purity in the mixed reaction was above 90% at pH values ​​from 10.2 to 12.3. As shown in Examples 2 and 6 to 8, the thiazolinethion derivative of Formula I-2, at reaction temperatures of 0°C, 10°C, and 20°C, had a product purity lowest at pH 7 (72.96%), and the product purity in the mixed reaction was above 90% at pH values ​​from 10.2 to 12.3. The thiazolinethion derivative exhibited high product purity (96.84%) at a low pH value (10.2) and high selectivity for the ε-amino group of the Lys side chain.

[0238] Comparative Examples 1 and 3 to 5 show that when using N-hydroxysuccinimide ester of Formula Ia as the amidation agent for the Lys side chain in the smegglutinin precursor, the product purity in the mixed reaction solution is low at pH values ​​from 7 to 12.3. Even at pH 10.2, the highest product purity is only 80.93%. Within the pH range of 7 to 12.3, its selectivity for the ε-amino group of the Lys side chain is lower than that of the thiazolinthion derivative. Comparative Examples 2 and 6 to 8 show that when using 2,4-dichloro-6-sulfonic acid phenol ester of Formula Ib as the activating agent for the Lys side chain, the product purity in the mixed reaction solution is greater than 90% only under strongly alkaline conditions (pH values ​​from 11.2 to 12.3). At low pH values ​​(7 and 10.2), its selectivity for the ε-amino group of the Lys side chain is significantly lower than that of the thiazolinthion derivative.

[0239] Based on the thiazoline thione derivative of this application, as an amidation reagent for the Lys side chain in the smegglutinin precursor, it exhibits high selectivity for the ε-amino group of the Lys side chain, which is beneficial for obtaining high-purity amidated products, reducing purification processes and costs, and facilitating large-scale production. In addition, as a novel peptide amidation reagent, it can achieve highly selective amidation of the side chain amino group within a wide pH window (especially at pH 10.2) and under low temperature conditions, thus having wider applicability. Furthermore, the leaving group thiazoline-2-thione in the thiazoline thione derivative can be efficiently recovered through organic solvent extraction and other methods and can be recycled, reducing material costs.

[0240] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. A thiazolinethione derivative or a salt thereof, characterized in that, The thiazolinethion derivative has the structure shown in Formula I: ; Wherein, R1 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of the substituents of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy; R2 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy. R1 may be the same as or different from R2; n is an integer from 1 to 50.

2. The thiazolinethion derivative or its salt according to claim 1, characterized in that, R1 is selected from C1-C8 alkyl or benzyl, and R2 is selected from hydrogen.

3. The thiazolinethion derivative or its salt according to claim 1, characterized in that, The thiazolinethion derivative is selected from at least one of the following compounds: 、 。 4. The use of the thiazolinethion derivative or its salt according to any one of claims 1 to 3 in the aminoacylation of amino acids, polypeptides or proteins, characterized in that, The amino acid, the polypeptide, and the protein each contain a side chain amino group.

5. The use of the thiazolinthion derivative or its salt according to any one of claims 1 to 3 in the preparation of glucagon-like peptide-1 receptor agonist polypeptide drugs, characterized in that, The glucagon-like peptide-1 receptor agonist polypeptide drug is used to treat diabetes or obesity.

6. A method for amidation of a polypeptide, characterized in that, The process includes the following steps: the polypeptide and any one of the thiazolinethion derivatives or their salts according to claims 1 to 3 are subjected to an amidation reaction in an aqueous system to obtain an amidated product; the pH value of the amidation reaction is 5 to 13.5, and the temperature is -15°C to 50°C; the polypeptide contains a side chain amino group.

7. The amidation method for polypeptides according to claim 6, characterized in that, The aqueous phase system includes a phosphate buffer solution and a first organic solvent; by volume percentage, the phosphate buffer solution accounts for more than or equal to 80% and less than 100% of the aqueous phase system; the first organic solvent is selected from at least one of N,N-dimethylformamide, N-methylpyrrolidone, acetonitrile, and acetone.

8. The amidation method for polypeptides according to claim 6, characterized in that, The pH value of the amidation reaction is 10 to 13; and / or, The molar ratio of the thiazolinethion derivative or its salt to the polypeptide is 1:1 to 1:2; and / or, The amidation reaction is performed at a temperature ranging from -15°C to 25°C.

9. The amidation method for a polypeptide according to any one of claims 6 to 8, characterized in that, After the amidation reaction is completed, the leaving groups released by the thiazoline thione derivative or its salt in the aqueous phase system after the reaction are recovered by organic solvent extraction; the organic solvent extraction method uses a second organic solvent for extraction, the second organic solvent being selected from at least one of ethyl acetate, isopropyl acetate, methyl tert-butyl ether, and dichloromethane.

10. The amidation method for a polypeptide according to any one of claims 6 to 8, characterized in that, The thiazolinethion derivative has the structure shown in Formula I: ; Wherein, R1 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of the substituents of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy; R2 is selected from H, C1-C8 alkyl, C1-C8 alkoxy, benzyl, benzyl substituted with at least one of C1-C8 alkyl and C1-C8 alkoxy, or C1-C8 alkyl substituted with C1-C8 alkoxy. R1 may be the same as or different from R2; n is 16; The structure of the polypeptide is shown in Formula II: ; II; The structure of the amidation product is shown in Formula III: ; III.